Contraception
Volume 78, Issue 6 , Pages 459-464 , December 2008

The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women

Received 16 April 2008 ,Revised 28 July 2008 ,Accepted 28 July 2008.

References 

  1. Burr DB, Yoshikawa T, Teegarden D, et al. Exercise and oral contraceptive use suppress the normal age-related increase in bone mass and strength of the femoral neck in women 18–31 years of age. Bone. 2000;27:855–863
  2. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434–441
  3. Cromer BA, Bonny AE, Stager M, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril. 2008;[electronic publication ahead of print]
  4. Hartard M, Kleinmond C, Wiseman M, et al. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone. 2007;40:444–450
  5. Lloyd T, Taylor DS, Lin HM, et al. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil Steril. 2000;74:734–738
  6. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception. 2006;73:445–469
  7. Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception. Contraception. 2007;75:438–443
  8. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:576–582
  9. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129:671–676
  10. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;303:13–16
  11. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17:17–21
  12. Tharnprisarn W, Taneepanichskul S. Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: a cross-sectional study in young Thai women. Contraception. 2002;66:101–103
  13. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception. 2002;65:407–410
  14. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67–76
  15. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73:470–487
  16. Cromer BA, Lazebnik R, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. 2005;192:42–47
  17. Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fractures. Contraception. 2006;73:571–576
  18. Cooper C, Hannaford P, Croft P, Kay CR. Oral contraceptive pill use and fractures in women: a prospective study. Bone. 1993;14:41–45
  19. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception. 1998;57:231–235
  20. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet. 1999;353:1481–1484
  21. Barad D, Kooperberg C, Wactawski-Wende J, et al. Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertil Steril. 2005;84:374–383
  22. Watson KC, Lentz MJ, Cain KC. Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Women's Health Issues. 2006;16:346–352
  23. Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female army recruits. Osteoporos Int. 2001;12:35–42
  24. Gissel T, Poulsen CS, Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf. 2007;6:267–278
  25. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287:2398–2399
  26. Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. Dan Med Bull. 1999;46:263–268
  27. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1–10
  28. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies: I. Principles. Am J Epidemiol. 1992;135:1019–1028
  29. Capella D. Descriptive tools and analysis. In:  Dukes MNG editors. Drug Utilization Studies: Methods and Uses. Copenhagen: WHO Regional Publications; 1993;p. 55–78European Series No. 45
  30. Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J. The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med. 1997;10:203–205
  31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383
  32. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol. 2003;56:221–229
  33. Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44:82–84
  34. Miettinen OS. Theoretical epidemiology: principles of occurrence research in medicine. 1st ed.. New York: Wiley & Sons; 1985;
  35. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16:155–162
  36. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ. 1997;315:841–846
  37. Vestergaard P, Mosekilde L. Fracture risk associated with smoking — a meta-analysis. J Intern Med. 2003;254:572–583

☆ The Danish Medical Research Council granted financial support (grant number 22-04-0495).

PII: S0010-7824(08)00396-X

doi: 10.1016/j.contraception.2008.07.014

Contraception
Volume 78, Issue 6 , Pages 459-464 , December 2008

Article Tools